Effectiveness and safety of once-weekly Semaglutide in patients with type 2 diabetes undergoing hemodialysis.
Not Applicable
Recruiting
- Conditions
- Patients with type 2 diabetes undergoing hemodialysis
- Registration Number
- JPRN-UMIN000047221
- Lead Sponsor
- Sohbudai Nieren Clinic
- Brief Summary
weekly semaglutide is a safe and effective option for glycemic control and weight management in obese people with T2D on HD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who refused to participate in this research.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in glucose profiles before and after semaglutide administration
- Secondary Outcome Measures
Name Time Method HbA1c, Glycated albumin, Interdialysis weight, Side effect